Aurobindo Pharma announced on Tuesday the collaboration with the Biotechnology Industry Research Assistance Council (BIRAC), created by the Department of Biotechnology for the development of the COVID-19 vaccine.
BIRAC has facilitated the establishment of the ‘r-VSV vaccine’ manufacturing platform for the first time in India by supporting the development of Aurobindo Pharma’s COVID-19 vaccine, the company said in a regulatory document.
Aurobindo Pharma said it is developing a vaccine for COVID-19 through its wholly-owned US subsidiary, Auro Vaccines. The candidate vaccine is based on a company’s proprietary vaccine delivery platform.
“Aurobindo is in the process of establishing a state-of-the-art manufacturing facility for viral vaccines that will be used to produce the COVID-19 vaccine and other viral vaccines. The plant will meet global standards. The development of the company’s COVID-19 vaccine is proceeding according to plan, ”the document added.
Commenting on the collaboration, Aurobindo Pharma Managing Director N Govindarajan said: “It is a source of immense pride that BIRAC has placed its trust in our vaccine capabilities. The senior leadership of Aurobindo and Auro Vaccines has extensive experience in the development, production and commercialization of various vaccines ”. The secretary of the Department of Biotechnology and president of BIRAC, Renu Swarup, said that the partnership with Aurobindo is to address the country’s need for a vaccine to combat this pandemic.
“The government is focused on creating an ecosystem that nurtures and encourages new product innovation to address the issues most relevant to our society,” Swarup added.
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the pharmaceutical companies in India working on the coronavirus vaccine.
.
